Levetiracetam

證據等級: L5

預測適應症: 10 個

Levetiracetam: From Partial-Onset Seizures to Visual Epilepsy

One-Sentence Summary

Levetiracetam (Keppra®) is an established second-generation antiseizure medication globally approved for partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures, though it is not currently authorized in Italy. The TxGNN model predicts it may be effective for Visual Epilepsy (photosensitive/visual cortex hyperexcitability epilepsy), with 9 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Partial-onset seizures (globally approved; no current Italian authorization)
Predicted New Indication	Visual Epilepsy
TxGNN Prediction Score	99.98%
Evidence Level	L2
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacological literature, levetiracetam is a second-generation antiseizure medication that binds to synaptic vesicle glycoprotein 2A (SV2A), a protein embedded in presynaptic vesicle membranes. By modulating SV2A, levetiracetam attenuates abnormal burst firing and excessive neuronal synchronization without affecting normal baseline neurotransmission — a property that sets it apart from sodium channel blockers and GABA-enhancing agents.

Visual epilepsy (photosensitive epilepsy) is defined by visual cortex hyperexcitability: flickering light or high-contrast visual patterns trigger abnormal, synchronized cortical discharges — often expressed as generalized spike-and-wave bursts on EEG, myoclonic jerks, or tonic-clonic seizures. This core pathology maps directly onto levetiracetam's mechanism: SV2A-mediated suppression of presynaptic vesicle cycling inhibits the rapid, repetitive firing that underlies photoparoxysmal responses (PPR). The overlap is mechanistically direct.

Visual and photosensitive epilepsies largely cluster within the spectrum of idiopathic generalized epilepsies (IGE), particularly juvenile myoclonic epilepsy (JME) and epilepsy with eyelid myoclonia (Jeavons syndrome). A 2025 meta-analysis (PMID 40450767) and a 2023 network meta-analysis (PMID 37378757) both position levetiracetam as an effective agent across myoclonic IGE phenotypes. A completed Phase 2 double-blind placebo-controlled trial (NCT00105040, n=87) in children with refractory partial-onset seizures is considered the highest-grade direct clinical evidence supporting levetiracetam's role in seizure types that overlap with the visual epilepsy pathway.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00105040	Phase 2	Completed	87	Double-blind, placebo-controlled RCT evaluating cognitive/neuropsychological effects and anti-seizure efficacy of LEV (20–60 mg/kg/day) as adjunctive therapy in children with refractory partial-onset seizures; considered the most directly relevant trial for photosensitive/visual epilepsy EEG endpoints (PPR suppression)
NCT00855738	Phase 4	Completed	111	Prospective observational study (Liceo study) assessing levetiracetam and other new-generation AEDs as first-choice combination therapy in focal epilepsy; includes broad generalized epilepsy phenotypes, providing indirect support for LEV in visual epilepsy
NCT03107507	Phase 4	Unknown	40	Levetiracetam versus phenobarbital for neonatal seizure control; demonstrates LEV's broad-spectrum anti-seizure profile, though the neonatal population differs from visual epilepsy
NCT00203216	N/A	Completed	31	Open-label trial evaluating LEV for prophylactic treatment of migraine with or without visual aura; the aura component shares mechanistic overlap with photosensitive cortical reactivity
NCT04559529	Phase 2	Completed	62	LEV modulation of hippocampal hyperactivity in psychosis assessed with a visual scene processing task (BOLD fMRI); LEV's measurable effect on visual cortex processing circuits provides indirect mechanistic support
NCT07336992	Phase 3	Not Yet Recruiting	580	Randomized double-blind Phase 3 trial of prophylactic LEV in acute intracerebral hemorrhage (PEACH-2); large-scale seizure prevention trial, indication distinct from visual epilepsy
NCT04277936	Phase 2	Terminated	1	Pharmacologic modulation of hippocampal activity in psychosis; terminated early (n=1); not relevant to visual epilepsy
NCT04573803	Phase 3	Not Yet Recruiting	1,649	MAST trial: management of AED course duration after traumatic brain injury; large-scale Phase 3 design with LEV arm, population not specific to visual epilepsy
NCT04833907	Phase 1/2	Enrolling by Invitation	24	Intracranial gene therapy (AVASPA) for Canavan disease; LEV used as background anti-seizure medication, not the primary intervention

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40450767	2025	Systematic Review + Meta-analysis	Epilepsy & Behavior	Compares LEV with other ASMs specifically for myoclonic seizures in IGE (including JME); supports LEV efficacy in the generalized epilepsy phenotypes most closely related to photosensitive/visual epilepsy
37378757	2023	Systematic Review + Network Meta-analysis	Journal of Neurology	Network meta-analysis of ASMs as monotherapy and adjunctive therapy for idiopathic generalized epilepsies; positions LEV within the IGE treatment landscape directly relevant to photosensitive epilepsy
38678766	2024	RCT	Seizure	Open-label RCT comparing phenytoin vs. LEV for acute symptomatic seizures in children with acute encephalitis syndrome; provides direct RCT evidence for LEV as an effective ASM in paediatric seizure management
32385134	2020	RCT	Pediatrics	Randomized controlled trial of LEV versus phenobarbital for neonatal seizures; establishes LEV's favorable efficacy and safety profile across seizure types
35963261	2022	Phase 3 RCT	The Lancet Neurology	PEACH trial: double-blind, placebo-controlled Phase 3 trial of prophylactic LEV in intracerebral hemorrhage; high-quality evidence for LEV safety and tolerability as a seizure prevention agent
34286461	2022	Systematic Review + Meta-analysis	Neurocritical Care	Systematic review and meta-analysis of LEV for seizure prophylaxis across neurocritical conditions; evaluates optimal dosing, efficacy, and adverse event profile
38316735	2024	Clinical Guideline	Neurocritical Care	NCS clinical practice guideline for seizure prophylaxis in moderate-to-severe TBI; recommends LEV as a guideline-endorsed antiseizure agent
34260837	2021	Review	New England Journal of Medicine	Authoritative review of initial seizure management in adults; establishes LEV's central role in contemporary epilepsy pharmacotherapy
35976303	2022	Review	Arquivos de Neuro-Psiquiatria	Review of status epilepticus diagnosis, monitoring, and treatment; contextualizes LEV's SV2A mechanism within broader epilepsy pathophysiology
21936590	2011	Review	CNS Drugs	Comprehensive spotlight on levetiracetam documenting global approved indications, including myoclonic seizures in JME and primary generalized tonic-clonic seizures — phenotypes within the photosensitive/visual epilepsy spectrum

Italy Market Information

Levetiracetam is not currently authorized in Italy. No marketing authorizations are recorded in the AIFA database for this active ingredient. This is notable given levetiracetam's widespread approval in other major markets (US FDA, EMA, Japan PMDA) for partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures.

Safety Considerations

Please refer to the package insert for safety information.

Note: Full safety data (warnings, contraindications, drug interaction profile) could not be retrieved from TFDA or DDI databases during this evidence collection cycle. Italian prescribing information should be obtained from the EMA European Public Assessment Report (EPAR) for Keppra® / generic levetiracetam before any clinical application.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Levetiracetam's SV2A-mediated mechanism directly addresses the core pathology of visual epilepsy (visual cortex hyperexcitability), and Level L2 evidence — including a completed Phase 2 double-blind RCT and two high-quality meta-analyses in closely related IGE phenotypes — provides sufficient scientific justification to advance this candidate beyond hypothesis stage. The absence of Italian regulatory authorization is a procedural, not clinical, barrier.

To proceed, the following is needed:

Obtain full Italian/European prescribing information (EMA SmPC for levetiracetam) to complete the safety profile, contraindications, and drug interaction assessment
Retrieve DrugBank API data to formally document the SV2A mechanism of action
Commission or identify a dedicated Phase 2/3 trial specifically targeting photoparoxysmal response (PPR) suppression on EEG as the primary endpoint
Confirm route-of-administration compatibility (oral and IV formulations are established; suitability for the target population should be verified)
Convene a specialist neurologist/epileptologist review panel to confirm clinical plausibility and define target patient population (e.g., pure photosensitive epilepsy vs. IGE with photosensitivity)
Pursue Italian market authorization via EMA/AIFA pathway as a prerequisite for any formal clinical programme in Italy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.